Should I buy or sell Nanobiotix stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NBTX shares. View NBTX analyst ratings or view top-rated stocks .

What is Nanobiotix's stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for Nanobiotix's stock. Their NBTX share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View analysts price targets for NBTX or view top-rated stocks among Wall Street analysts .

How have NBTX shares performed in 2024?

Nanobiotix's stock was trading at $7.28 on January 1st, 2024. Since then, NBTX shares have decreased by 24.5% and is now trading at $5.50. View the best growth stocks for 2024 here .

When is Nanobiotix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024. View our NBTX earnings forecast .

When did Nanobiotix IPO?

Nanobiotix (NBTX) raised $95 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO.

How do I buy shares of Nanobiotix?

Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NBTX

Nanobiotix (NBTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free NBTX Stock Alerts

$5.50

+0.12 (+2.23%)

(As of 04/18/2024 ET)

Compare

Today's Range: $5.31
▼
$5.54
50-Day Range: $5.38
▼
$7.63
52-Week Range: $1.75
▼
$11.00

Volume: 28,362 shs
Average Volume: 34,722 shs
Market Capitalization: $259.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get Nanobiotix alerts:

Nanobiotix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 100.0% Upside
$11.00 Price Target
Short Interest: Healthy
0.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.44 out of 5 stars

Medical Sector

473rd out of 918 stocks

Biotechnology Industry

16th out of 43 stocks

3.5

Analyst's Opinion

Consensus Rating
Nanobiotix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Nanobiotix has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.11% of the outstanding shares of Nanobiotix have been sold short.
Short Interest Ratio / Days to Cover
Nanobiotix has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nanobiotix has recently increased by 4.14%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Nanobiotix does not currently pay a dividend.
Dividend Growth
Nanobiotix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NBTX.

2.0

News and Social Media Coverage

News Sentiment
Nanobiotix has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Nanobiotix this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added Nanobiotix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nanobiotix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.45% of the stock of Nanobiotix is held by insiders.
Percentage Held by Institutions
Only 38.81% of the stock of Nanobiotix is held by institutions.

N/A

Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Nanobiotix Stock (NASDAQ:NBTX)

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

NBTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NBTX Stock News Headlines

April 17, 2024 | globenewswire.com

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

April 2, 2024 | globenewswire.com

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 6, 2024 | globenewswire.com

Nanobiotix to Present at Upcoming Investor Conferences in March

January 31, 2024 | finance.yahoo.com

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

January 30, 2024 | finanznachrichten.de

Nanobiotix S.A.: Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

January 29, 2024 | finance.yahoo.com

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

January 18, 2024 | seekingalpha.com

NBTX Nanobiotix S.A.

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

December 8, 2023 | realmoney.thestreet.com

Nanobiotix initiated with an Outperform at Leerink

December 4, 2023 | finance.yahoo.com

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

November 15, 2023 | finanznachrichten.de

Nanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

November 13, 2023 | finance.yahoo.com

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

November 9, 2023 | finance.yahoo.com

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

November 9, 2023 | finanznachrichten.de

Nanobiotix S.A.: Voting Rights and Shares Capital of the Company

November 7, 2023 | finance.yahoo.com

NANOBIOTIX Announces Closing of Global Offering

November 6, 2023 | finance.yahoo.com

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

November 2, 2023 | msn.com

Why Nanobiotix (NBTX) Stock Is Plunging Thursday

November 2, 2023 | finance.yahoo.com

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

November 2, 2023 | morningstar.com

Nanobiotix SA ADR NBTX

November 1, 2023 | finance.yahoo.com

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

October 23, 2023 | finance.yahoo.com

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

October 5, 2023 | msn.com

Nanobiotix falls after Phase 1 data for lead asset in head and neck cancer

October 5, 2023 | markets.businessinsider.com

UBS Reaffirms Their Buy Rating on Nanobiotix (NBTX)

October 4, 2023 | finance.yahoo.com

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months

September 29, 2023 | finance.yahoo.com

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

September 28, 2023 | finance.yahoo.com

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

See More Headlines

Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 4/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NBTX
CUSIP: N/A
CIK: 1760854
Web: www.nanobiotix.com
Phone: 33-1-40-26-04-70
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +103.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $5.12 million
Price / Sales: 49.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.82) per share
Price / Book: -6.59

Miscellaneous

Outstanding Shares: 47,130,000
Free Float: 45,507,000
Market Cap: $254.50 million
Optionable: Not Optionable
Beta: 0.21

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Laurent Levy Ph.D. (Age 51)
Co-Founder, President of the Executive Board & CEO
Comp: $674.57k
Mr. Bart Van Rhijn (Age 51)
CFO & Member of Executive Board
Comp: $598.42k
Ms. Anne-Juliette Hermant M.A. (Age 50)
Chief People Officer & Member of Executive Board
Comp: $328.98k
Mr. Earl J. Bergey Ph.d. (Age 69)
Co-Founder
Mr. Alain Dostie
Chief Operating Officer
Mr. Craig West CFA
Senior Vice President of Investor Relations
Mr. Brandon Owens
VP of Strategic Marketing & Corporate Communication
Mr. Patrick Tricoli M.B.A.
Pharm.D., Global Head of Business Development
Ms. Margaret Galluzzi
VP & Global Head of Clinical Operations
Mr. Ventzislav Vassilev M.D.
VP & Global Head of Safety Vigilance

Key Competitors

View All Competitors

Institutional Ownership

Baillie Gifford & Co.
Bought 932,835 shares on 1/26/2024
Ownership: 6.087%

View All Institutional Transactions

NBTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nanobiotix stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NBTX shares.
View NBTX analyst ratings or view top-rated stocks.
What is Nanobiotix's stock price target for 2024?: 2 Wall Street analysts have issued 1-year price objectives for Nanobiotix's stock. Their NBTX share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts price targets for NBTX or view top-rated stocks among Wall Street analysts.
How have NBTX shares performed in 2024?: Nanobiotix's stock was trading at $7.28 on January 1st, 2024. Since then, NBTX shares have decreased by 24.5% and is now trading at $5.50.
View the best growth stocks for 2024 here.
When is Nanobiotix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our NBTX earnings forecast.

When did Nanobiotix IPO?: Nanobiotix (NBTX) raised $95 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO.
How do I buy shares of Nanobiotix?: Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nanobiotix (NBTX) Stock Price, News & Analysis

Nanobiotix MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

About Nanobiotix Stock (NASDAQ:NBTX)

NBTX Stock Price History

NBTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

NBTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™